Tesamorelin
Also known as: Egrifta, TH9507, GHRH analog
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.
Evidence
Strong
FDA status
FDA-approved
Source
Synthetic GHRH analog with trans-3-hexenoic acid modification
Overview
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.
Mechanism of Action
Binds GHRH receptors on pituitary somatotrophs, stimulates pulsatile GH release, increases IGF-1, preferentially reduces visceral fat via GH-mediated lipolysis, minimal effect on subcutaneous fat.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Reduces visceral adipose tissue
- Improves body composition
- Lean body mass
- Enhances GH and IGF-1 levels
- Improves lipid profiles
- Thinking and memory (small trials)
Researched for
Includes FDA-approved uses where marked; other items are research topics, not approved uses.
How Gabriel approaches peptides
Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. Tesamorelin isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.
Research & Evidence
Phase 3 trials, FDA approved for HIV lipodystrophy
FDA-approved (Egrifta) to reduce excess abdominal fat in adults with HIV and lipodystrophy, based on trials showing lower visceral fat. Other uses are off-label or investigational.
Safety Information
Potential Side Effects
- •Injection site reactions
- •Arthralgia
- •Peripheral edema
- •Muscle pain
- •Elevated IGF-1
- •Glucose intolerance
Contraindications
- Active malignancy
- Diabetic retinopathy
- Pregnancy
- Breastfeeding
- Pituitary tumor
Interactions
- ⚠May affect glucose metabolism
- ⚠Monitor with diabetes medications
Quick Facts
Related Peptides
CJC-1295
Long-acting GHRH analog that stimulates sustained growth hormone release.
Ipamorelin
Selective ghrelin mimetic that triggers rapid growth hormone release without affecting cortisol or prolactin.
Sermorelin
Short-acting GHRH analog that stimulates natural pulsatile growth hormone release from the pituitary.